TimesSquare Capital Management LLC Acquires 109,835 Shares of CG Oncology, Inc. (NASDAQ:CGON)

TimesSquare Capital Management LLC raised its stake in CG Oncology, Inc. (NASDAQ:CGON) by 25.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 546,904 shares of the company’s stock after purchasing an additional 109,835 shares during the period. TimesSquare Capital Management LLC owned approximately 0.72% of CG Oncology worth $15,685,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. State Street Corp raised its stake in shares of CG Oncology by 73.0% in the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company’s stock valued at $64,166,000 after buying an additional 717,722 shares in the last quarter. Ally Bridge Group NY LLC increased its position in CG Oncology by 50.5% in the 3rd quarter. Ally Bridge Group NY LLC now owns 263,266 shares of the company’s stock valued at $9,933,000 after acquiring an additional 88,390 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in CG Oncology by 114.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company’s stock valued at $14,325,000 after acquiring an additional 202,262 shares in the last quarter. BNP Paribas Financial Markets increased its position in CG Oncology by 876.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company’s stock valued at $1,006,000 after acquiring an additional 23,931 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of CG Oncology by 59.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,071 shares of the company’s stock valued at $1,172,000 after purchasing an additional 11,542 shares during the last quarter. 26.56% of the stock is owned by institutional investors.

CG Oncology Stock Up 0.5 %

CGON stock opened at $27.52 on Thursday. The company has a fifty day moving average price of $29.23 and a two-hundred day moving average price of $33.46. CG Oncology, Inc. has a one year low of $25.77 and a one year high of $48.60.

Wall Street Analysts Forecast Growth

CGON has been the topic of several recent research reports. TD Cowen assumed coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research note on Friday, January 10th. UBS Group assumed coverage on shares of CG Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $60.00 price target on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a report on Friday, December 6th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $63.88.

Insider Activity

In related news, Director Hong Fang Song sold 700,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $28.00, for a total transaction of $19,600,000.00. Following the completion of the sale, the director now owns 3,003,931 shares of the company’s stock, valued at $84,110,068. This represents a 18.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $34.54, for a total value of $34,540.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 702,000 shares of company stock valued at $19,664,200.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.